Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Marco Davila, Senior Vice President and Associate Director for Translational Research at Roswell Park

“We’re armoring the T cells with IL-18, a cytokine that will help protect them from the suppressive microenvironment of the solid tumor”

Emese Zsiros, Principal Investigator and Chair of Gynecologic Oncology at Roswell Park

“Because ovarian cancer spreads through the peritoneal cavity, the CAR T-cell therapy will be delivered in two ways: intravenously and into the peritoneal cavity”

Dinesh de Alwis, Senior Vice President and Head of Clinical Drug Development at Generate Biomedicines

“Recognizing a tumor antigen is only one part of the challenge. In solid tumors, a CAR T cell that kills but does not expand or persist is a partial solution. GB-5267 was computationally designed with potency, proliferation, and persistence to maintain activity in a suppressive tumor microenvironment. Dosing the first patient begins the clinical test of whether that function-first approach behaves in patients as intended”

Emese Zsiros, Principal Investigator and Chair of Gynecologic Oncology at Roswell Park

“CAR T-cell therapy has transformed outcomes in blood cancers”

Emese Zsiros, Principal Investigator and Chair of Gynecologic Oncology at Roswell Park

“With this clinical trial, we are working to bring that progress to people with ovarian cancer”